首页> 美国卫生研究院文献>BMJ Global Health >Market-driven value-based advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB

【2h】

Market-driven value-based advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB

机译：以市场为导向基于价值的预先承诺（MVAC）：加速开发具有突破性的通用药物疗法以终结结核病

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Tuberculosis (TB) is the world’s deadliest infectious disease; without a significant technological breakthrough, current trajectories suggest that the world will not achieve the Convergence 2035 targets for TB until 2074, almost 40 years later than originally projected.

机译：结核病（TB）是世界上最致命的传染病；在没有重大技术突破的情况下，当前的趋势表明，世界要到2074年才能实现结核病的融合2035年目标，比原先的预计晚了40年。

著录项

期刊名称 BMJ Global Health
作者
Kalipso Chalkidou; Adrian Towse; Rachel Silverman; Martina Garau; Ganesh Ramakrishnan;
展开▼
作者单位

展开▼
年(卷),期 2020(5),4
年度 2020
页码 -1
总页数 6
原文格式 PDF
正文语种
中图分类
关键词
tuberculosis; health economics; health systems evaluation; infections; diseases; disorders; injuries; health policies and all other topics;

机译：结核病;卫生经济学;卫生系统评估;感染;疾病;疾病;伤害;卫生政策和所有其他主题;

相似文献

外文文献
中文文献
专利

1. Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development [J] . Nuermberger Eric, Sizemore Christine, Romero Klaus, Antimicrobial agents and chemotherapy. . 2016,第3期

机译：建立基于证据的非临床路线图，以评估新结核病（TB）药物方案的功效：结核病药物方案的关键途径-过敏和感染性疾病国家研究所在体内TB药物开发的体内药理学研讨会
2. Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen [J] . EdelineJ., LoriotY., CulineS., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2012,第8期

机译：先前接受铂-吉西他滨方案治疗的晚期膀胱癌患者的加速MVAC化疗
3. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies (vol 18, pg 1, 2018) [J] . Tiberi D., du Plessis N., Walzl G., The Lancet infectious diseases . 2018,第6期

机译：结核病：新药，治疗方案和寄主针对治疗的进展和进展（Vol 18，PG 1,2018）
4. The Effect of Knowledge Sharing on Affective Commitment: The Mediation Role of Competency Development of Gen Y Employees at PT PP (Persero), Tbk Head Office [C] . Nara Pangestika Vidyani, Putri Mega Desiana International Conference on Business and Management Research . 2018

机译：知识分享对情感承诺的影响：PT PP（Persero），TBK总裁Gen Y员工能力发展的调解作用
5. Accelerating Drug Development with Health-Consumer-Contributed Data and Heterogeneous Network Mining [D] . Zhao, Mengnan . 2019

机译：通过健康消费者贡献的数据和异构网络挖掘加速药物开发
6. Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development [O] . Eric Nuermberger, Christine Sizemore, Klaus Romero, 2016

机译：建立基于证据的非临床路线图以评估新结核病（TB）药物方案的功效：结核病药物方案的关键途径-过敏和感染性疾病国家研究院体内药理学研讨会结核病药物开发
7. Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB [O] . Kalipso Chalkidou, Adrian Towse, Rachel Silverman, 2020

机译：市场驱动，基于价值的，推进承诺（MVAC）：加速开发疏忽普遍药物方案的开发结束结核病

Market-driven value-based advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB

摘要

著录项

相似文献

相关主题

期刊订阅